Completed PHASE3 INTERVENTIONAL 2-arm NCT00265642

Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C (Fibrosar)

Study of the Effects of a Sartan on Hepatic Fibrosis Progression in Chronic Viral Hepatitis C

Sponsor: ANRS, Emerging Infectious Diseases

Updated 6 times since 2017 Last updated: Feb 6, 2014 Started: Oct 31, 2006 Primary completion: Apr 30, 2013 Completion: Nov 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hepatitis C, Chronic, this trial is completed. The trial is conducted by ANRS, Emerging Infectious Diseases and has accumulated 6 data snapshots since 2006. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Oct 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Oct 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ANRS, Emerging Infectious Diseases
Sanofi

Data source: ANRS, Emerging Infectious Diseases

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Angers, France